NCT00627952 is a Phase 3 clinical trial of amlodipine 10 mg in Hypertension, sponsored by University of Erlangen-Nürnberg Medical School.

Who is sponsoring NCT00627952?

NCT00627952 is sponsored by University of Erlangen-Nürnberg Medical School.

What drugs are being tested in NCT00627952?

Interventions in NCT00627952: amlodipine 10 mg, manidipine 20 mg, amlodipine 5 mg + delapril 30 mg, manidipine 10 mg + delapril 30 mg.

What condition does NCT00627952 study?

NCT00627952 studies Hypertension.

Is NCT00627952 still recruiting?

NCT00627952 is currently completed. Last updated 18 January 2013.

Last reviewed 2013-01-18 · How we verify

NCT00627952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double Blind, Randomized, Parallel Group, Multicentre Study to Evaluate the Effects of Manidipine 20 MG Vs. Amlodipine 10 MG and the Combination of Manidipine 10 MG Plus Delapril 30 MG Vs. Amlodipine 5 MG Plus Delapril 30 MG on Intraglomerular Pressure in Hypertensive Patients

Completed Phase 3 Last updated 18 January 2013

What this trial tests

Phase 3 trial testing amlodipine 10 mg in Hypertension in 100 participants. Completed in 1 December 2008.

Timeline

1 November 2007

Primary endpoint
1 December 2008

1 December 2008

Quick facts

Lead sponsor	University of Erlangen-Nürnberg Medical School
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 November 2007
Primary completion	1 December 2008
Estimated completion	1 December 2008
Sites	1 location across Germany

Drugs / interventions tested

amlodipine 10 mg
manidipine 20 mg — full drug profile →
amlodipine 5 mg + delapril 30 mg — full drug profile →
manidipine 10 mg + delapril 30 mg — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 18 to 65, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

effect of manidipine 20 mg once daily compared to amlodipine 10 mg once daily on intraglomerular pressure
Time frame: 4 weeks

Sponsor's own description

Eight-week multi-national, multicenter, randomized, double blind, active control, two arms, parallel groups study with a 4-week single drug treatment (manidipine or amlodipine) phase followed by a 4-week combination treatment (manidipine + delapril or amlodipine + delapril) phase.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Retinal capillary rarefaction in patients with untreated mild-moderate hypertension.
Bosch AJ, Harazny JM, Kistner I, Friedrich S, et al · · 2017 · cited 41× · PMID 29268712 · DOI 10.1186/s12872-017-0732-x
Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension.
Ott C, Schneider MP, Raff U, Ritt M, et al · · 2013 · cited 23× · PMID 23240643 · DOI 10.1111/j.1365-2125.2012.04336.x
Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus.
Jumar A, Harazny JM, Ott C, Friedrich S, et al · · 2016 · cited 19× · PMID 27935938 · DOI 10.1371/journal.pone.0162608

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other University of Erlangen-Nürnberg Medical School trials

Trials by the same sponsor.

NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00627952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
Last refreshed: 18 January 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00627952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing